News >

Kulke Sheds Light on Emerging Agents for Neuroendocrine Tumors

Danielle Bucco
Published: Tuesday, Feb 06, 2018

Matthew Kulke, MD

Matthew Kulke, MD
Several emerging agents are rapidly advancing the treatment paradigm for patients with neuroendocrine tumors (NETs).

, Matthew Kulke, MD, a medical oncologist at Dana-Farber Cancer Institute, discussed the evolving treatment paradigm for patients with NETs.

OncLive: What exciting advancements have occurred in the treatment of patients with NETs?

Kulke: There are several new treatments that are focused on tumor control for patients with NETs. For example, there is a phase II study of cabozantinib, a tyrosine kinase inhibitor that targets VEGF and c-MET. The study showed encouraging results, leading us to believe that cabozantinib will be taken forward into a large randomized trial that is designed as a registration study. Hopefully, we will get another new treatment for patients with NETs. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Navigating Treatment Decisions in mCRC: Sequencing Through Multiple Lines of CareMar 26, 20201.5
Community Practice Connections™: Optimizing Care in the Era of an Expanding Armamentarium for Hepatocellular CarcinomaMar 29, 20202.0
Publication Bottom Border
Border Publication